Ranbaxy’s subsidiary launches esomeprazole in UK
05 Sep 2011
Ranbaxy Laboratories Ltd said its UK's wholly-owned subsidiary Ranbaxy (UK) Ltd. had successfully launched esomeprazole 20mg and 40mg tablets.
Esomeprazole is the first approved generic bio-equivalent version of AstraZeneca's prescription drug Nexium in the UK, with an annual sale of £60 million, as per IMS June 2011 data.
Esomeprazole is used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (FORD/GERD) and Zollinger-Ellison syndrome, the company said with its filing with the Bombay Stock Exchange.
The company said the product would be offered through pharmacies, retail and wholesale stores with immediate effect.